Daily non-political popular news in brief.
Mayo Clinic Cancer Center -- individualizing treatment for multiple myeloma patients
12-10-2006 · EurekAlert!Researchers at Mayo Clinic Cancer Center, in cooperation with industry partners, have, for the first time, identified tumor specific alterations in the cellular pathway by which the multiple myeloma drug bortezomib (Velcade) works, and they have identified nine new genetic mutations in cancer cells that should increase a patient's chance of responding to the agent.
Read more »
Keywords: mayo, clinic, cancer, center, individualizing, treatment, multiple, myeloma, patients, patient
« Previous | Next »
Similar news on "Mayo Clinic Cancer Center -- individualizing treatment for multiple myeloma patients":
- Mayo Clinic -- Collaborating to move treatment research forward
12-12-2006 · EurekAlert!
Novel therapies are greatly improving the long-term outlook for patients with multiple myeloma, say researchers at Mayo Clinic Cancer Center, who have led efforts in testing these treatments and moving them quickly into first-line therapies.
Similar news · Read more »
- Investigating the measles virus as a tool to kill multiple myeloma
03-05-2007 · EurekAlert!
Mayo Clinic Cancer Center has opened a new Phase I clinical trial testing an engineered measles virus against multiple myeloma, a cancer of the bone marrow that currently has no cure.
Similar news · Read more »
- Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma
04-15-2007 · EurekAlert!
Mayo Clinic Cancer Center researchers have found that chaetocin, a by-product of a common wood mold, has promise as a new anti-myeloma agent. Results of their study, being presented today at the American Association for Cancer Research annual meeting, show the by-product to be more effective than currently used therapies at killing multiple myeloma cells.
Similar news · Read more »
- New therapeutic options for newly diagnosed multiple myeloma patients
12-10-2007 · EurekAlert!
Mayo Clinic researchers today presented results of a phase II trial of myeloma induction therapy -- a first step therapy designed to reduce cancer cells numbers -- with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D) showing an improved response over the traditional lenalidomide-dexamethasone (L-Dex) therapy.
Similar news · Read more »
- Multiple myeloma clinical trial closes early
04-04-2007 · EurekAlert!
Mayo Clinic Cancer Center announced today that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone.
Similar news · Read more »
- Nonhormonal drug reduces hot flashes in men treated for prostate cancer
06-03-2007 · EurekAlert!
North Central Cancer Treatment Group researchers based at Mayo Clinic in Rochester, Minn., have discovered that low doses of a drug used to prevent epileptic seizures and to treat nerve pain caused by shingles substantially reduces hot flashes in patients who are undergoing anti-hormonal treatment, or androgen-deprivation therapy, for prostate cancer.
Similar news · Read more »
- Octogenarians are not too old for cancer surgery
11-27-2006 · EurekAlert!
Mayo Clinic Cancer Center researchers have found that a radical prostatectomy can be a viable option for select octogenarian patients. The findings, which run counter the conventional practice of generally avoiding surgeries for individuals over 80 years old solely based on age, are available today in Urology.
Similar news · Read more »
- Research shows survival benefit for leukemia patients treated with arsenic trioxide
06-04-2007 · EurekAlert!
Through participation in a government-sponsored multi-year study, researchers at the Comprehensive Cancer Center at Wake Forest University have helped confirm that arsenic trioxide -- marketed as Trisenox -- significantly improves patient survival when coupled with standard chemotherapy treatment in newly diagnosed patients with acute promyelocytic leukemia, or APL.
Similar news · Read more »
- Penn's Abramson Cancer Center part of major phase III study for myeloma
11-21-2007 · EurekAlert!
Researchers from the UPenn's Abramson Cancer Center announced today that findings from two international clinical trials show unprecedented survival for patients with myeloma, a cancer the blood-making cells of bone marrow. Findings show that with the oral drug lenalidomide, in combination with dexamethasone, patients significantly improved by all measures where previous treatments had failed -- including a median survival of nearly three years -- the longest median survival known for this difficult to treat patient group.
Similar news · Read more »
- Vorinostat shows anti-cancer activity in recurrent gliomas
06-03-2007 · EurekAlert!
North Central Cancer Treatment Group (NCCTG) researchers, based at Mayo Clinic in Rochester, Minn., report that a novel application of the drug vorinostat shows activity in patients with recurrent glioblastoma multiforme.
Similar news · Read more »
